Eiger BioPharmaceuticals, Inc. announced the commercial launch and availability of Zokinvy™ (lonafarnib) in the United States. Zokinvy was approved by the U.S. Food and Drug Administration (FDA) in November 2020 to reduce the risk of death in patients with Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) and for the treatment of processing-deficient progeroid laminopathies. Most of the identified Zokinvy-eligible patients in the U.S. have received Zokinvy through Eiger's global expanded access program and are now enrolled in Eiger OneCare which will facilitate a smooth transition to Zokinvy commercial supply.